Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Atara Biotherapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 32 | 37 | +5 |
| Shares | 1.80M | 1.88M | +79.8K (+4.4%) |
| Value | $13.9M | $27.0M | +$13.1M (+93.8%) |
New holders (9)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 22,060 | $316.1K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 17,109 | $245.0K | 0.00% |
| Quadrature Capital Ltd | 16,542 | $236.9K | 0.00% |
| Globeflex Capital L P | 15,458 | $221.5K | 0.03% |
| Private Wealth Asset Management, LLC | 900 | $12.9K | 0.00% |
| Tower Research Capital LLC (TRC) | 342 | $4.90K | 0.00% |
| Kerr Financial Planning Corp | 24 | $322 | 0.00% |
| Alexis Investment Partners, LLC | 15 | $215 | 0.00% |
| Rockefeller Capital Management L.P. | 8 | $115 | 0.00% |
Sold out (4)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Vestal Point Capital, LP | 94,085 | $726.3K |
| Citadel Advisors LLC | 23,003 | $177.6K |
| Raymond James Financial Inc | 4,021 | $31.0K |
| Raiffeisen Bank International AG | 200 | $1.54K |